Clonality: monoclonal
Host: Mouse
Source: Biotrend
Cat# COX13-M
Formulation: Ig fraction
Reacts in: Human





Comments / Questions

No Available Comments

Make a comment or submit a question

To make a comment you must login or register.


No Available References

Further Reading


  1. Lilly Halts IDENTITY Trials as Patients Worsen on Secretase Inhibitor
  2. Research Brief: More Evidence That CSF Aβ Changes Precede AD
  3. Draft Framework for National AD Plan Released
  4. NAPA and the National Plan—Is Your Input Getting Through?
  5. Induced Neurons From AD Patients Hint at Disease Mechanisms
  6. Astrocyte Imaging Supports Early Inflammation in the AD Brain
  7. Intracellular Aβ Causes Neurodegeneration in Mice
  8. Mice Tell Tale of Tau Transmission, Alzheimer’s Progression
  9. Beyond Aβ: Other APP Fragments Affect Neuron Health and Disease
  10. San Francisco: Tweaking Brain ApoE Reduces Aβ, Symptoms
  11. HHS Seeks Input on Draft National Plan
  12. Would Congress Please SPRINT Toward Cures?
  13. Miami: Amyloid PET in the Clinic: What Are the Issues?
  14. Miami: Longitudinal Amyloid PET Data Start Converging
  15. Research Brief: Expanded Registry to Grow DIAN Population
  16. Antioxidants No Help for Alzheimer’s, Biomarker Trial Says
  17. Keystone: Symposium Emphasizes Key Aspects of ApoE Biology
  18. FDA Approves Amyvid for Clinical Use
  19. News Brief: Sebelius Gives Report on U.S. Alzheimer's Plan
  20. Synthetic Synuclein Corrupts Native Along Mouse Brain Networks
  21. Imaging Inflammation: Can Glial PET Tracers Make a Mark?
  22. DIAN Grows, Gets Ready for Therapeutic Trials
  23. Q&A With Ryan Watts, Genentech Lead Scientist on API Trial
  24. ApoE4 Makes Blood Vessels Leak, Could Kick Off Brain Damage
  25. Coming to a City Near You: Tracer to Picture Brain Amyloid
  26. Amyloid Imaging Task Force to Work Out Technology's Use
  27. Aβ Sufficient for Seeding—But Is It a Prion?
  28. Communication Breakdown: Multiple Networks Decline in AD Brains
  29. Protective APP Mutation Found—Supports Amyloid Hypothesis
  30. Profilin Gene Is Actin’ in ALS
  31. Experimental α7 Agonist Meets Cognitive and Clinical Endpoints
  32. No Pony in There: Bapi Fails Mild to Moderate ApoE4 Carriers
  33. When Is a C9ORF72 Repeat Expansion Not a C9ORF72 Repeat Expansion?
  34. Wave of New BACE Inhibitors Heading to Phase 2
  35. CSF Markers: Goodbye, Research Use Only; Hello, Clinical
  36. Me, Too: Florbetaben, Flutemetamol Look Good in Trial
  37. Soluble Aβ Takes Blame for Hyperactive Neurons in Mouse Brain
  38. Synaptic Plasticity Falters Early in AD Mice
  39. Collaborative Umbrella CAPs Three Prevention Trial Initiatives
  40. Clinical Trials of Intravenous Bapineuzumab Halted
  41. iPSC Disease Models Up and Coming for AD, Down’s, ALS
  42. FTD Risk Factor Confirmed, Alters Progranulin Pathways
  43. Phase 3 Solanezumab Trials "Fail"—Is There a Silver Lining?
  44. New AlzRisk Analysis: Brain Injury Promotes Dementia, But Is It AD?
  45. Who Will Pay for New Amyloid Scans? The Lobbying Has Begun
  46. Bapineuzumab Phase 3: Target Engagement, But No Benefit
  47. Dementia Four Times More Likely in Pro Football Players
  48. ENCODE Turns Human Genome From Sequence to Machine
  49. Newly Mapped DNA Elements Help Interpret GWAS
  50. C9ORF72 Steals the Show at Frontotemporal Dementia Meeting
  51. Will Tau Drug Show Its True Colors in Phase 3 Trials?
  52. The Solanezumab Benefit: Oh, So Small, But Probably Real
  53. DIAN Trial Picks Gantenerumab, Solanezumab, Maybe BACE Inhibitor
  54. Mutations in TREM2 Cause Frontotemporal Dementia
  55. ApoE4 Promotes Aβ Oligomerization
  56. Ironing Out Apoptotic Role for New APP-Binding Protein
  57. CTAD: New Data on Sola, Bapi, Spark Theragnostics Debate
  58. CTAD: Regulatory Science Gains Prominence in AD Research
  59. CTAD: Adaptive Antibody Trial to Try Bayesian Statistics
  60. Biomarker Progress? Picking the New, Better Measuring the Old
  61. CTAD: EEG Gains Luster as More Trials Incorporate Biomarkers
  62. Meet the New Progressive Tauopathy: CTE in Athletes, Soldiers
  63. Boxing: Study of Human Model for CTE Enters Second Round
  64. Soothing Neuroinflammation Quells Plaques in Mice
  65. SfN: Tau Toxicity in the Limelight
  66. Merck Launches Largest Trial of BACE Inhibitor in AD
  67. Could β-Arrestin Provide New Way to Halt Aβ Accumulation?
  68. Solanezumab Heads for New Phase 3 Trial
  69. Insurance Coverage of AD Diagnostics? Not Without Better Data
  70. To Reveal or Not to Reveal? New Data on the Question
  71. Expanding the Network, DIAN Starts Showing Longitudinal Data
  72. Thousands of Whole Genomes to Be Mined for New Clues to AD
  73. API Echoes DIAN: Biomarker Changes Precede Symptoms by 20 Years
  74. Enter the New Alzheimer’s Gene: TREM2 Variant Triples Risk
  75. Toxic Synuclein Corrupts Native in Wild-Type Mice
  76. Déjà Vu? AD Patients Again Look Worse on γ-Secretase Inhibitor
  77. CTE Advocates Pivot Toward Preventing Concussions in Kids
  78. Drug Company Halts Development of γ-Secretase Inhibitor Avagacestat
  79. Natural History-Cum-Trials Initiative, Grants to Boost Down’s Research
  80. Does ApoE4 Lower Brain Metabolism Independently of Aβ?
  81. Microglia and AD—Does the Inflammasome Drive Aβ Pathology?